Abstract
V. di Lorenzo, Noémi Csorba, Renáta Szabó, Levente Kollár, Yvette Roske, Ivan Ranđelović, Krisztina Balázs, Tibor Viktor Szalai, Nina‐Louisa Efrém, Levente Mihalovits, Tı́mea Imre, József Simon, József Tóvári, Marc Nazaré, Oliver Daumke, Péter Ábrányi‐Balogh, György Miklós Keserű
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A Comprehensive Review of SHP2 and Its Role in Cancer
10.1007/s13402-022-00698-1 · 2022
Tyrosine Phosphatase PTPN11/SHP2 in Solid Tumors - Bull’s Eye for Targeted Therapy?
10.3389/fimmu.2024.1340726 · 2024
Setting Sail: Maneuvering SHP2 Activity and Its Effects in Cancer
10.1016/bs.acr.2023.03.003 · 2023
Allosteric Inhibition of SHP2 Phosphatase Inhibits Cancers Driven by Receptor Tyrosine Kinases
10.1038/nature18621 · 2016
Strategies to Overcome Drug Resistance Using SHP2 Inhibitors
10.1016/j.apsb.2021.03.037 · 2021
Allosteric SHP2 Inhibitors in Cancer: Targeting the Intersection of RAS, Resistance, and the Immune Microenvironment
10.1016/j.cbpa.2020.11.007 · 2021
Crystallographic Landscape of SHP2 Provides Molecular Insights for SHP2 Targeted Drug Discovery
10.1002/med.21890 · 2022
Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules
10.1016/j.ejmech.2024.116579 · 2024
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
10.1021/acs.jmedchem.3c02118 · 2024
Recent Advances in the Discovery of Protein Tyrosine Phosphatase SHP2 Inhibitors
10.1039/d1md00386k · 2022
The Ascension of Targeted Covalent Inhibitors
10.1021/acs.jmedchem.1c02134 · 2022
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: An Update
10.1021/acs.jmedchem.3c01825 · 2024
Advanced Approaches of Developing Targeted Covalent Drugs
10.1039/d2md00216g · 2022
Advancements, Challenges, and Future Frontiers in Covalent Inhibitors and Covalent Drugs: A Review
10.1016/j.ejmcr.2024.100217 · 2024
Targeted Covalent Inhibitors for Novel Therapeutics
10.4155/fmc-2023-0243 · 2023
Profiling Nuclear Cysteine Ligandability and Effects on Nuclear Localization Using Proximity Labeling-Coupled Chemoproteomics
10.1016/j.chembiol.2023.11.010 · 2024
Allosteric Covalent Inhibitors of the STAT3 Transcription Factor from Virtual Screening
10.1021/acsmedchemlett.4c00622 · 2025
An Intracellular Peptide Library Screening Platform Identifies Irreversible Covalent Transcription Factor Inhibitors
10.1002/advs.202416963 · 2025
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
10.1021/acs.jmedchem.3c02403 · 2024
Covalent Fragment Mapping of KRasG12C Revealed Novel Chemotypes with in Vivo Potency
10.1016/j.ejmech.2023.115212 · 2023
Blocking C-Terminal Processing of KRAS4b via a Direct Covalent Attack on the CaaX-Box Cysteine
10.1073/pnas.2410766122 · 2025
Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D
10.1021/jacs.5c03562 · 2025
Discovering Uncharted Binding Pockets on E3 Ligases Leads to the Identification of FBW7 Allosteric Modulators
10.1002/advs.202506068 · 2025
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
10.3389/fchem.2021.691093 · 2021
Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
10.1021/acschembio.8b01083 · 2019
Drug Discovery Approaches to Target E3 Ligases
10.1002/cbic.202400656 · 2025
Covalent Fragment Approaches Targeting Non-Cysteine Residues
10.1016/j.tips.2023.08.014 · 2023
Design of Next-Generation Covalent Inhibitors: Targeting Residues beyond Cysteine
10.1016/bs.armc.2020.10.001 · 2020
Advancing Covalent Ligand and Drug Discovery beyond Cysteine
10.1021/acs.chemrev.5c00001 · 2025
The Expanding Repertoire of Covalent Warheads for Drug Discovery
10.1016/j.drudis.2023.103799 · 2023
Covalent Inhibitors: To Infinity and Beyond
10.1021/acs.jmedchem.4c01308 · 2024
A Proteome-Wide Atlas of Lysine-Reactive Chemistry
10.1038/s41557-021-00765-4 · 2021
Mapping the SHP2 Allosteric Pocket With Target-Biased Covalent Fragments
10.1002/cbic.70310 · 2026
An Electrophilic Warhead Library for Mapping the Reactivity and Accessibility of Tractable Cysteines in Protein Kinases
10.1016/j.ejmech.2020.112836 · 2020
Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments
10.1002/cbic.202000700 · 2020
Dual Allosteric Inhibition of SHP2 Phosphatase
10.1021/acschembio.7b00980 · 2018
Design, Synthesis and Biological Evaluation of Novel Triazoloquinazolinone and Imidazoquinazolinone Derivatives as Allosteric Inhibitors of SHP2 Phosphatase
10.1080/14756366.2022.2078968 · 2022
Design, Synthesis, and Biological Evaluation of Novel Triazoloquinazolinone Derivatives as SHP2 Protein Inhibitors
10.1080/14756366.2021.1986491 · 2021
Crystal Structure, DFT Study, Hirshfeld Surface Analysis, Molecular Docking and Antitumor Activity of a Novel SHP2 Inhibitor
10.1016/j.molstruc.2023.137320 · 2024
Electrophilic Warheads in Covalent Drug Discovery: An Overview
10.1080/17460441.2022.2034783 · 2022
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
10.1021/acs.biochem.0c00104 · doi-reference
Fitting of Kinact and KI Values from Endpoint Pre-Incubation IC50 Data
10.1021/acsmedchemlett.4c00054 · doi-reference
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors
10.1021/acs.jmedchem.4c01721 · doi-reference
Cell-Active, Irreversible Covalent Inhibitors Targeting a Surface-Exposed Non-Catalytic Lysine on Aurora a Kinase by Using Squarate Chemistry
10.1002/ange.202510763 · doi-reference
Synthesis of Triazoloquinazolinone Based Compounds as Tubulin Polymerization Inhibitors and Vascular Disrupting Agents
10.1016/j.ejmech.2016.03.056 · doi-reference
Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values
10.1021/ct200133y · doi-reference
PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical p K a Predictions
10.1021/ct100578z · doi-reference
Very Fast Prediction and Rationalization of PKa Values for Protein-Ligand Complexes
10.1002/prot.22102 · doi-reference
Intrinsic Reactivity Profile of Electrophilic Moieties to Guide Covalent Drug Design:: N -α-Acetyl-l-Lysine as an Amine Nucleophile
10.1039/c6md00017g · doi-reference
Profiling Sulfur(VI) Fluorides as Reactive Functionalities for Chemical Biology Tools and Expansion of the Ligandable Proteome
10.1021/acschembio.2c00633 · doi-reference
A Road Map for Prioritizing Warheads for Cysteine Targeting Covalent Inhibitors
10.1016/j.ejmech.2018.10.010 · doi-reference
Global Profiling of Lysine Reactivity and Ligandability in the Human Proteome
10.1038/nchem.2826 · doi-reference
Electrophilic Warheads in Covalent Drug Discovery: An Overview
10.1080/17460441.2022.2034783 · doi-reference
Crystal Structure, DFT Study, Hirshfeld Surface Analysis, Molecular Docking and Antitumor Activity of a Novel SHP2 Inhibitor
10.1016/j.molstruc.2023.137320 · doi-reference
Design, Synthesis, and Biological Evaluation of Novel Triazoloquinazolinone Derivatives as SHP2 Protein Inhibitors
10.1080/14756366.2021.1986491 · doi-reference
Design, Synthesis and Biological Evaluation of Novel Triazoloquinazolinone and Imidazoquinazolinone Derivatives as Allosteric Inhibitors of SHP2 Phosphatase
10.1080/14756366.2022.2078968 · doi-reference
Dual Allosteric Inhibition of SHP2 Phosphatase
10.1021/acschembio.7b00980 · doi-reference
Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments
10.1002/cbic.202000700 · doi-reference
An Electrophilic Warhead Library for Mapping the Reactivity and Accessibility of Tractable Cysteines in Protein Kinases
10.1016/j.ejmech.2020.112836 · doi-reference
Mapping the SHP2 Allosteric Pocket With Target-Biased Covalent Fragments
10.1002/cbic.70310 · doi-reference
A Proteome-Wide Atlas of Lysine-Reactive Chemistry
10.1038/s41557-021-00765-4 · doi-reference
Covalent Inhibitors: To Infinity and Beyond
10.1021/acs.jmedchem.4c01308 · doi-reference
The Expanding Repertoire of Covalent Warheads for Drug Discovery
10.1016/j.drudis.2023.103799 · doi-reference
Advancing Covalent Ligand and Drug Discovery beyond Cysteine
10.1021/acs.chemrev.5c00001 · doi-reference
Design of Next-Generation Covalent Inhibitors: Targeting Residues beyond Cysteine
10.1016/bs.armc.2020.10.001 · doi-reference
Covalent Fragment Approaches Targeting Non-Cysteine Residues
10.1016/j.tips.2023.08.014 · doi-reference
Covalent Activation of the C-Type Lectin DC-SIGN
10.1002/anie.202520594 · doi-reference
Drug Discovery Approaches to Target E3 Ligases
10.1002/cbic.202400656 · doi-reference
Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
10.1021/acschembio.8b01083 · doi-reference
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
10.3389/fchem.2021.691093 · doi-reference
Discovering Uncharted Binding Pockets on E3 Ligases Leads to the Identification of FBW7 Allosteric Modulators
10.1002/advs.202506068 · doi-reference
Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D
10.1021/jacs.5c03562 · doi-reference
Blocking C-Terminal Processing of KRAS4b via a Direct Covalent Attack on the CaaX-Box Cysteine
10.1073/pnas.2410766122 · doi-reference
Covalent Fragment Mapping of KRasG12C Revealed Novel Chemotypes with in Vivo Potency
10.1016/j.ejmech.2023.115212 · doi-reference
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
10.1021/acs.jmedchem.3c02403 · doi-reference
An Intracellular Peptide Library Screening Platform Identifies Irreversible Covalent Transcription Factor Inhibitors
10.1002/advs.202416963 · doi-reference
Allosteric Covalent Inhibitors of the STAT3 Transcription Factor from Virtual Screening
10.1021/acsmedchemlett.4c00622 · doi-reference
Profiling Nuclear Cysteine Ligandability and Effects on Nuclear Localization Using Proximity Labeling-Coupled Chemoproteomics
10.1016/j.chembiol.2023.11.010 · doi-reference
Targeted Covalent Inhibitors for Novel Therapeutics
10.4155/fmc-2023-0243 · doi-reference
Advancements, Challenges, and Future Frontiers in Covalent Inhibitors and Covalent Drugs: A Review
10.1016/j.ejmcr.2024.100217 · doi-reference